ANNUAL REPORT 2012 - TiGenix

(12)
The shares were subscribed to by Gemma Frisius-Fonds K.U.Leuven NV (114,285 A), Katholieke Universiteit Leuven (28,571 C),
Universiteit Gent (28,571 C), ING België NV (2,714,285 E), Capricorn Venture Fund II NV (231,428 E), Fagus NV (428,571 E), Auriga
Ventures II FCPR (428,571 E, ), Fortis Private Equity Venture Belgium NV (428,571 E), Baekeland Fonds II NV (114,285 E) and HSS
Ventures Inc. (28,571 E). Subsequently, ING België NV sold a number of its new shares to ITX Corporation (200,000 E), Partners@
Venture NV (285,714 E), Ferdinand Verdonck and Margriet Van Houtte (28,572 E), Kris Vansanten (36,000 E), Werner Vanlembergen
(36,000 E), BGL Investment Partners SA (142,857 E) and Technowal SA (71,428 E).
(13)
The warrants were issued on March 22, 2001 and exercised in 2006 by Nancy Veulemans (3,750 D), Jenny Peeters (1,250 D), Johan
Vanlauwe (2,500 D) and Etienne Schacht (20,000 D).
(14)
The warrants were issued on March 13, 2000 and exercised in 2006 by Axxis V&C BVBA (187,500 B) and Prof. Dr. Frank Luyten
(187,500 B).
(15)
The 8,000,000 shares were subscribed to at the occasion of the initial public offering. Upon completion of the initial public
offiering, all existing shares were converted into common shares.
(16)
The over-allotment warrants were exercised by Piper Jaffray Ltd. (1,200,000).
(17)
The existing shareholder warrants were exercised by Axxis V&C BVBA (91,748), Prof. Dr. Frank Luyten (91,748), Katholieke Universiteit
Leuven (52,717), Gemma Frisius-Fonds K.U. Leuven NV (182,754), Johan Bellemans (3,557), Etienne Schacht (5,336) and Universiteit
Gent (66,205).
(18)
The warrants were issued on September 15 and 30, 2003 and exercised in 2008.
(19)
The warrants were issued on September 15 and 30, 2003 and exercised in 2008.
(20)
The warrants were issued on May 14, 2004 and exercised in 2009.
(21)
The shares were subscribed to by Particon B.V. (340,000), N.V. Industriebank LIOF (340,000), Limburg Ventures B.V. (200,000) and
LRM NV (200,000).
(22)
The 3,010,589 shares were subscribed to at the occasion of the contribution in kind in the framework of the Orthomimetics
acquisition that occurred in November 2009.
(23)
The 2,204,300 shares were subscribed to at the occasion of the private placement that was done in December 2009.
(24)
The warrants were issued on March 20, 2008 and exercised in 2010.
(25)
The capital increase was performed through the contribution in kind of part of the receivable of former shareholders of
Orthomimetics Limited (now : TiGenix Ltd) resulting from their sale of 680,686 Orthomimetics shares, valued at EUR 3.4 million, to
TiGenix on November 30, 2009 and marks the second phase of the Orthomimetics acquisition.
(26)
The 44,814,402 shares were subscribed to at the occasion of the contribution of all of the Cellerix SA (now : TiGenix SAU) shares.
(27)
The 15,187,111 shares were subscribed to at the occasion of a public offering of shares with preferential subscription right.
(28)
The capital increase was performed through the contribution in kind of the last part of the receivable of former shareholders of
Orthomimetics Limited (now : TiGenix Ltd) resulting from their sale of 680,686 Orthomimetics shares, valued at EUR 3.4 million, to
TiGenix on November 30, 2009 and marks the third and last phase of the Orthomimetics acquisition.
(29)
Capital decrease through the absorption of losses carried forward as shown in the annual accounts as per December 31, 2011,
without cancellation of shares.
(30)
The 8,629,385 shares were subscribed to at the occasion of the private placement that was carried out in December 2012.
33